Literature DB >> 22898384

Predictors of survival in contemporary practice after initial radiosurgery for brain metastases.

Anna Likhacheva1, Chelsea C Pinnix, Neil R Parikh, Pamela K Allen, Mary F McAleer, Max S Chiu, Erik P Sulman, Anita Mahajan, Nandita Guha-Thakurta, Sujit S Prabhu, Daniel P Cahill, Dershan Luo, Almon S Shiu, Paul D Brown, Eric L Chang.   

Abstract

PURPOSE: The number of brain metastases (BM) is a major consideration in determining patient eligibility for stereotactic radiosurgery (SRS), but the evidence for this popular practice is equivocal. The purpose of this study was to determine whether, following multivariate adjustment, the number and volume of BM held prognostic significance in a cohort of patients initially treated with SRS alone. METHODS AND MATERIALS: A total of 251 patients with primary malignancies, including non-small cell lung cancer (34%), melanoma (30%), and breast carcinoma (16%), underwent SRS for initial treatment of BM. SRS was used as the sole management (62% of patients) or was combined with salvage treatment with SRS (22%), whole-brain radiation therapy (WBRT; 13%), or resection (3%). Median follow-up time was 9.4 months. Survival was determined using the Kaplan-Meier method. Cox regression was used to assess the effects of patient factors on distant brain failure (DBF), local control (LC), and overall survival (OS).
RESULTS: LC at 1 year was 94.6%, and median time to DBF was 10 months. Median OS was 11.1 months. On multivariate analysis, statistically significant predictors of OS were presence of extracranial disease (hazard ratio [HR], 4.2, P<.001), total tumor volume greater than 2 cm(3) (HR, 1.98; P<.001), age ≥60 years (HR, 1.67; P=.002), and diagnosis-specific graded prognostic assessment (HR, 0.71; P<.001). The presence of extracranial disease was a statistically significant predictor of DBF (HR, 2.15), and tumor volume was predictive of LC (HR, 4.56 for total volume >2 cm(3)). The number of BM was not predictive of DBF, LC, or OS.
CONCLUSIONS: The number of BM is not a strong predictor for clinical outcomes following initial SRS for newly diagnosed BM. Other factors including total treatment volume and systemic disease status are better determinants of outcome and may facilitate appropriate use of SRS or WBRT.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22898384     DOI: 10.1016/j.ijrobp.2012.05.047

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

Review 1.  Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.

Authors:  Lorenza Landi; Federico Cappuzzo
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.

Authors:  Valerio Nardone; Sara Nanni; Pierpaolo Pastina; Claudia Vinciguerra; Alfonso Cerase; Pierpaolo Correale; Cesare Guida; Antonio Giordano; Paolo Tini; Alfonso Reginelli; Salvatore Cappabianca; Luigi Pirtoli
Journal:  Strahlenther Onkol       Date:  2019-05-23       Impact factor: 3.621

3.  Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery.

Authors:  Or Cohen-Inbar; Patrick Melmer; Cheng-chia Lee; Zhiyuan Xu; David Schlesinger; Jason P Sheehan
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

4.  Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer.

Authors:  Kyung Rae Cho; Min Ho Lee; Doo-Sik Kong; Ho Jun Seol; Do-Hyun Nam; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park; Sung Tae Kim; Do Hun Lim; Jung-Il Lee
Journal:  J Neurooncol       Date:  2015-09-15       Impact factor: 4.130

5.  Identifying candidates for gamma knife radiosurgery among elderly patients with brain metastases.

Authors:  Tae Hoon Roh; Mi Sun Choi; Namkyu You; Donghwan Jeong; Ae Hwa Jang; Mi Ra Seo; Sang Ryul Lee; Se-Hyuk Kim
Journal:  J Neurooncol       Date:  2018-01-11       Impact factor: 4.130

6.  Local control after fractionated stereotactic radiation therapy for brain metastases.

Authors:  Selvan Rajakesari; Nils D Arvold; Rachel B Jimenez; Laura W Christianson; Margaret C Horvath; Elizabeth B Claus; Alexandra J Golby; Mark D Johnson; Ian F Dunn; Eudocia Q Lee; Nancy U Lin; Scott Friesen; Edward G Mannarino; Matthew Wagar; Fred L Hacker; Stephanie E Weiss; Brian M Alexander
Journal:  J Neurooncol       Date:  2014-07-25       Impact factor: 4.130

7.  Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal disease.

Authors:  Paul M Foreman; Bradford E Jackson; Karan P Singh; Andrew K Romeo; Barton L Guthrie; Winfield S Fisher; Kristen O Riley; James M Markert; Christopher D Willey; Markus Bredel; John B Fiveash
Journal:  J Clin Neurosci       Date:  2017-12-14       Impact factor: 1.961

8.  Stereotactic radiosurgery for newly diagnosed brain metastases: comparison of three dose levels.

Authors:  Dirk Rades; Dagmar Hornung; Oliver Blanck; Kristina Martens; Mai Trong Khoa; Ngo Thuy Trang; Michael Hüppe; Patrick Terheyden; Jan Gliemroth; Steven E Schild
Journal:  Strahlenther Onkol       Date:  2014-03-25       Impact factor: 3.621

Review 9.  Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.

Authors:  Wenhui Wang; Xin Sun; Zhouguang Hui
Journal:  Oncol Res Treat       Date:  2019-09-17       Impact factor: 2.825

10.  Stereotactic radiosurgery to the resection cavity for brain metastases: prognostic factors and outcomes.

Authors:  Ryan J Abel; Lingyun Ji; Cheng Yu; Ariel Lederman; Thomas Chen; Charles Liu; Gabriel Zada; Paul E Kim; Michael Apuzzo; Eric L Chang
Journal:  J Radiosurg SBRT       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.